,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mW2AQ'}, 'Id': 'a0POZ000005f4mW2AQ', 'Event_Date__c': '2020-02-23', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BUllQAG'}, 'change': None}]",Feb 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that ribociclib in combination with fulvestrant for the second-line treatment of HR-positive, HER2-negative locally advanced breast cancer who have failed previous endocrine therapy be funded with high priority subject to the same Special Authority criteria as previously recommended for palbociclib in this setting.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the different priority assigned to ribociclib and palbociclib was primarily due to differences in the quality of data currently available for these agents.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that based on currently available data there was a class effect from CDK4/6 inhibitors in the treatment of HR-positive HER2-negative locally advanced breast cancer and <b>recommended</b> funding for patients to receive one line of treatment with a CDK4/6 inhibitor in either a first or second-line setting with high priority.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reiterated its previous recommendation that the following Special Authority criteria be applied to funding of CDK4/6 inhibitors (note combined first-line and second-line criteria are shown below):</p><p><span style=""font-size: 9pt;"">Special Authority for Subsidy – Retail Pharmacy</span></p><p><span style=""font-size: 9pt;"">Initial application -</span><b style=""font-size: 9pt;""> </b><span style=""font-size: 9pt;"">only from a medical oncologist or </span><span style=""font-size: 10pt;"">any other </span><span style=""font-size: 9pt;"">medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has unresectable locally advanced or metastatic breast cancer; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming disease is hormone-receptor positive and HER2-negative; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance score of 0-2; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has relapsed or progressed during prior endocrine therapy; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior systemic treatment for metastatic disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[CDK4/6 inhibitor] must be used in combination with an endocrine partner.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Renewal application - only from a medical oncologist or </span><span style=""font-size: 10pt;"">any other </span><span style=""font-size: 9pt;"">medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[CDK4/6 inhibitor] must be used in combination with an endocrine partner; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of progressive disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate and the patient is benefitting from treatment.</span></p><p><br></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that ribociclib in combination with fulvestrant for the second-line treatment of HR-positive, HER2-negative locally advanced breast cancer who have failed previous endocrine therapy be funded with high priority subject to the same Special Authority criteria as previously recommended for palbociclib in this setting.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the different priority assigned to ribociclib and palbociclib was primarily due to differences in the quality of data currently available for these agents.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that based on currently available data there was a class effect from CDK4/6 inhibitors in the treatment of HR-positive HER2-negative locally advanced breast cancer and <b>recommended</b> funding for patients to receive one line of treatment with a CDK4/6 inhibitor in either a first or second-line setting with high priority.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reiterated its previous recommendation that the following Special Authority criteria be applied to funding of CDK4/6 inhibitors (note combined first-line and second-line criteria are shown below):</p><p><span style=""font-size: 9pt;"">Special Authority for Subsidy – Retail Pharmacy</span></p><p><span style=""font-size: 9pt;"">Initial application -</span><b style=""font-size: 9pt;""> </b><span style=""font-size: 9pt;"">only from a medical oncologist or </span><span style=""font-size: 10pt;"">any other </span><span style=""font-size: 9pt;"">medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has unresectable locally advanced or metastatic breast cancer; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming disease is hormone-receptor positive and HER2-negative; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance score of 0-2; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has relapsed or progressed during prior endocrine therapy; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior systemic treatment for metastatic disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[CDK4/6 inhibitor] must be used in combination with an endocrine partner.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Renewal application - only from a medical oncologist or </span><span style=""font-size: 10pt;"">any other </span><span style=""font-size: 9pt;"">medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[CDK4/6 inhibitor] must be used in combination with an endocrine partner; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of progressive disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate and the patient is benefitting from treatment.</span></p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently three CDK4/6 inhibitors marketed internationally (abemaciclib, palbociclib and ribociclib), each with slightly different dosing schedules, inhibiting CDK4/6 at slightly different concentrations, and each with slightly differing reports of adverse events. However, the Subcommittee considered that currently available evidence indicates there is a class effect from use of these agents in the treatment of HR-positive HER2-negative locally advanced breast cancer. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that three funding applications for two CDK4/6 inhibitor agents (palbociclib and ribociclib) had been previously considered by both PTAC and CaTSoP, however both committees had previously considered the totality of data for the class of agents that was available at the time. </p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following summary of previous consideration and recommendations regarding funding applications for CDK4/6 inhibitors for HR-positive, HER2-negative locally advanced breast cancer:</p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">  </span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""color: white;"">The Subcommittee noted that a fourth application, for ribociclib as a second-line treatment, had been received subsequent to PTAC’s consideration of CDK4/6 inhibitors in May 2019 and that to date no funding application for abemaciclib had been received.</span></p><p>Ribociclib applications</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the primary evidence from ribociclib in the treatment of HR-positive HER2-negative locally advanced breast cancer comes from three studies – MONALEESA 2, MONALEESA 3 and MONALEESA 7.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that MONALEESA‑2 is a phase\xa03 randomized, double-blind, placebo-controlled trial of first-line ribociclib plus letrozole compared with placebo plus letrozole in 668 postmenopausal women with HR-positive, HER2-negative advanced breast cancer (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29718092"" target=""_blank"">Hortobagyi et al. Ann Oncol. 2018;29:1541-7</a>). </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients received ribociclib in 28-day treatment cycles (600\u2009mg/day; 3-weeks-on/1-week-off) until disease progression, unacceptable toxicity, death, or discontinuation for any other reason; and that treatment crossover was not permitted.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The primary end point was locally assessed PFS, per RECIST v1.1 and considered that as compared to centrally assessed endpoints, this could introduce inconsistency to the data. The Subcommittee noted that at a median follow-up of 26.4 months, the median PFS was 25.3 months in the palbociclib arm compared with 16.0 month in the placebo/letrozole arm (HR 0.568; 95% CI 0.457 to 0.704; log-rank P = 9.63 x 10-8). </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the key secondary end point was OS however OS data remained immature, with 50 deaths in the ribociclib arm and 66 in the placebo arm (HR 0.746, 95% CI 0.517 – 1.078).</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the most frequent all-cause grade 3/4 AEs (≥15% in either arm; ribociclib plus letrozole versus placebo plus letrozole) were neutropenia and leukopenia.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that overall, 192 patients (57.5%) in the ribociclib plus letrozole arm had at least one ribociclib/placebo dose reduction versus 26 (7.9%) in the placebo plus letrozole arm; most patients required a single dose reduction [115 (34.4%) versus 20 (6.1%), respectively].</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that quality of life data from MONALEESA-2 indicated that this was not diluted with use of ribociclib over time and the lower pain scores with ribociclib would be clinically meaningful for patients.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that MONALEESA-7 is a phase 3, randomised, double-blind, placebo-controlled trial of ribociclib plus endocrine therapy compared with placebo and endocrine therapy in 672 pre or perimenopausal women with HR-positive, HER2-negative advanced breast cancer who had not previously received a CDK4/6 inhibitor (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29804902"" target=""_blank"">Tripathy et al. Lancet Oncol. 2018;19:904-15</a>). </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that eligibility criteria included locoregionally recurrent or metastatic disease not amenable to curative therapy (eg not candidates for curative surgery or radiotherapy), up to one previous line of chemotherapy for advanced disease, and no previous treatment with a CDK4/6 inhibitor.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that that patients could receive either tamoxifen (36%) or a nonsteroidal aromatase inhibitor (64%) as endocrine therapy all with goserelin. The Subcommittee noted treatment crossover was not permitted and considered this was a similar study design to MONALEESA-2.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the primary endpoint was investigator-assessed progression-free survival and at a median follow-up of 19.2 months, that the median PFS was 23.8 months in the ribociclib arm compared with 13.0 months in the placebo/endocrine therapy arm (HR 0.55; 95% CI 0.44 to 0.69; P&lt;0.0001).</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that median progression-free survival per the central assessment of the independent masked review cohort (n=267) was not reached (95% CI 19·9 months–not reached) among the 133 patients assessed in the ribociclib group and 11·1 months (7·4–16·9) in the 134 patients assessed in the placebo group (HR 0·43, 95% CI 0·29–0·63).</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that overall survival results were not mature at the time of this analysis, with 89 deaths recorded in total at data cut-off (43 [13%] in the ribociclib group and 46 [14%] in the placebo group); and that the study remains masked for further follow-up of overall survival.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that MONALEESA-3 is a phase III, double-blind, placebo-controlled<span style=""color: black;""> trial of </span>ribociclib plus fulvestrant compared with placebo plus fulvestrant in 484 postmenopausal women with HR-positive, HER2-negative advanced (metastatic or locoregionally recurrent disease not amenable to curative treatment) breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29860922"" target=""_blank"">Slamon et al. J Clin Oncol. 2018;36:2465-72</a>). The Subcommittee considered this was a similar trial design to MONALEESA-2 and-7 except for the 2:1 randomisation.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that exclusion criteria included prior treatment with chemotherapy for advanced disease, fulvestrant, or a CDK4/6 inhibitor.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that at a median follow-up of 20.4 months, that the median PFS was 20.5 months in the ribociclib arm compared with 12.8 months in the placebo/fulvestrant arm (HR 0.593; 95% CI 0.480 to 0.732; P&lt;0.001). The Subcommittee noted that the median PFS in patients who were treatment-naïve in this trial was not reached in the ribociclib arm compared with 18.3 months in the placebo/fulvestrant arm.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the OS data were reported as immature by Slamon et al 2018, with a total of 70 deaths (14.5%) were observed in the ribociclib arm versus 50 (20.7%) in the placebo arm.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that Novartis had provided unpublished data from a second OS interim analysis at a median follow-up of 39.4 months, which includes 275 deaths (78% of the total 351 events). The Subcommittee noted that the estimated hazard ratio from this second OS interim analysis was 0.724 (95% CI: 0.568, 0.924; p-value 0.00455). The Subcommittee noted that the p-value threshold to claim significance = 0.01129 and therefore OS was considered to be statistically significant despite median OS having been not reached (NR) in the ribociclib arm and was 40.0 months (95% CI: 37.0, NE) in the placebo arm. The Subcommittee noted that median OS in the treatment-naïve (first-line) subgroup was NR vs 45.1\u2009months (HR, 0.700 [95% CI, 0.479-1.021]) and in the second-line subgroup was 40.2 vs 32.5\u2009months (HR, 0.730 [95% CI, 0.530-1.004]). The Subcommittee noted that this OS data was presented at <a href=""https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Overall-survival-OS-results-of-the-Phase-III-MONALEESA-3-trial-of-postmenopausal-patients-pts-with-hormone-receptor-positive-HR-human-epidermal-growth-factor-2-negative-HER2-advanced-breast-cancer-ABC-treated-with-fulvestrant-FUL-ribocicl"" target=""_blank"">ESMO 2019</a> and that as per protocol, these OS results will be considered final.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that all three MONALEESA studies have shown an OS benefit from use of ribociclib for the treatment of HR-positive HER2-negative advanced breast cancer.</p><p>Advice requested by PTAC </p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that in August 2019 PTAC had recognised that there were some differences in the records of PTAC and CaTSoP’s consideration of the funding applications for these agents (likely based on the different but complementary expertise, experience, and perspectives each committee brought to its consideration under the Factors for Consideration). The Subcommittee noted that PTAC considered it would be useful that CaTSoP clarify its advice about CDK4/6 inhibitors so that PTAC could further consider its priorities and recommendations for this class of agents.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that in particular PTAC asked if CaTSoP could provide a more detailed evidence review and discussion about:</p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>Why the health need of a second-line population was rated higher than the first-line setting, but that the recorded recommendation was that funding of CDK4/6 inhibitors as a class was a lower priority for use in second-line than in first-line. </p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>More details about CaTSoP’s interpretation of the evidence for differences in outcomes such as for overall survival (OS), progression-free survival (PFS), and quality of life in both first- or second-line settings for late breast cancers. </p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>More details about CaTSoP’s assessment the OS benefit, its magnitude, and precision, for the different treatment settings, and the evidence used for this advice.</p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>in the context of CDK4/6 inhibitors, advice on: the strength and quality of available evidence for the use of surrogate outcomes specifically for locally advanced or metastatic breast cancers, particularly those that are HR-positive and/or HER2-negative, and thus the applicability of such outcomes data in this setting.</p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that previously treated (second-line) patients were considered to have a higher health need than those in the first-line population as they would be more symptomatic and have likely to exhaust their endocrine options more quickly. However, the Subcommittee considered that in April 2019 the relative funding priority for all second-line patients was considered to be slightly lower than that in the first-line setting due to the quality of evidence and likely higher absolute level of benefit in terms of PFS and OS in a first-line setting. Although, members noted that this does not include those second-line patients with hormone sensitive disease where the data in this subgroup is considered to be stronger than in a general second-line population.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the updated survival data for ribociclib from MONALEESA-3 and MONALEESA-7 reinforced the signal of a class effect from use of CDK4/6 inhibitors in the treatment of HR-positive HER2-negative advanced breast cancer. </p><p><span style=""color: black;"">1.29.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that benefit from use of CDK4/6 inhibitor has been demonstrated across both first and second-line populations. The Subcommittee considered that the differences in trial results is likely to have been driven by heterogeneity of the trial populations, such as the number of patients with endocrine-sensitive disease or ESR-1 mutation rates, although this was based on expert opinion and not supported by any current data.</p><p><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that a benefit from CDK4/6 inhibitors is reported in both first-line post-menopausal patients and first-line pre-menopausal patients treated with ovarian suppression with the strength of evidence best for those who receive aromatase inhibitor and goserelin. The Subcommittee considered that patients with hormone-sensitive disease appear to get the most benefit from use of a CDK4/6 inhibitor in a second-line setting; and that the durability of response for the overall second-line population is likely to be slightly shorter than when used in a first-line HR-positive HER2-negative advanced breast cancer population.</p><p><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that of the various trials for use of the three CDK4/6 inhibitor agents with currently published evidence, the ribociclib trials were of highest quality due to their clinical trial design, which meant that OS could be demonstrated, whereas the survival data from the palbociclib and abemaciclib trials were compromised by the crossover design.</p><p><span style=""color: black;"">1.32.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that there is good quality evidence that CDK4/6 inhibitors provide a PFS of around 10 to 12 months and around a 30% improvement in OS (in a disease setting where it is difficult to demonstrate OS gain) both of which were clinically meaningful for patients with HR-positive HER2-negative advanced breast cancer. </p><p><span style=""color: black;"">1.33.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that while improving OS is considered the most important therapeutic goal in advanced breast cancer, it has been difficult to demonstrate an OS advantage in clinical trials in advanced breast cancer populations and particularly in a first-line setting. The Subcommittee considered this is both because powering studies to show OS requires very large patient numbers and also because heterogeneous populations with long post progression survival, crossover and heterogeneous post study therapy as well as the evolving treatment standards for these patients all impact on study outcomes.</p><p><span style=""color: black;"">1.34.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that it had considered some of the issues and challenges related to clinical trial design, surrogate outcomes and critical appraisal at its meeting in <a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">July 2019</a>. </p><p><span style=""color: black;"">1.35.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that in advanced breast cancer there is evidence to support the use of surrogate measure, such as PFS, for OS including a number of systematic reviews across a variety of advanced breast cancer patient populations. </p><p><span style=""color: black;"">1.36.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee acknowledged that the quality of these reviews was variable (the number of trials included in these reviews and the number of patients in the trials included differed, some reviews use all lines of therapy whereas some restrict to first or second line) almost all of these reviews addressed the issue of PFS as a surrogate measure for OS in metastatic disease.</p><p><span style=""color: black;"">1.37.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that some reviews did not show any correlation between PFS and OS while other showed a modest correlation (square correlation statistic ranged from 0.1-0.57), however considered that the more tightly the population was defined the better the correlation became for example HR-positive, HER2-negative disease in premenopausal women.</p><p><span style=""color: black;"">1.38.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee also noted a<span style=""color: black;""> study of mBC patients and oncology care providers (</span>nurses<span style=""color: black;""> and oncologists) in the US aimed at evaluating by the value of OS, PFS, and other treatment attributes in treatment decision by surveys designed to assess preferences for OS/PFS and stable disease and the timing thereof, preferences for level of evidence and toxicity rates as well as willingness to pay for specific treatment attributes (</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589981/"" target=""_blank"">MacEwan et al MDM Policy Pract. 2019; 4: 2381468319855386</a><span style=""color: black;"">).</span></p><p>General comments</p><p><span style=""color: black;"">1.39.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that on 1 September 2019, PHARMAC issued a <a href=""https://www.pharmac.govt.nz/news/rfp-2019-09-01-cdk4-cdk6/"" target=""_blank"">Request for Proposals</a> for the supply of a CDK4/CDK6 inhibitor for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer; and that this process was seeking commercial bids from the suppliers of these medicines for use as both first and second-line treatment for patients who meet the Special Authority criteria detailed in the RFP document (as recommended by CaTSoP in April 2019). The Subcommittee considered it would be a preferred outcome for both first and second-line populations to be funded as a result of this competitive process.</p><table class=""ql-table-blob"" border=""1"" style=""width: 441.4pt; margin-left: 28.1pt;"" width=""589""><tbody><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">\xa0</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">\xa0</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p align=""center"" class=""MsoBodyText"" style=""text-align: center;""><b>CaTSoP</b></p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p align=""center"" class=""MsoBodyText"" style=""text-align: center;""><b>PTAC</b></p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""5"" rowspan=""1"" valign=""top"" width=""589"" style=""width: 441.4pt;"">\n  <p class=""MsoBodyText"">Chemical</p>\n  </td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">Palbociclib</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium (September 2018)</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Low (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">second-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Medium (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">Ribociclib</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by CaTSoP</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Low (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">second-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by CaTSoP.</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by PTAC.</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""5"" rowspan=""1"" valign=""top"" width=""589"" style=""width: 441.4pt;"">\n  <p class=""MsoBodyText"">Class </p>\n  </td></tr><tr><td colspan=""1"" rowspan=""3"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">CDK4/6 inhibitors</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">High priority (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""3"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Class effect associated with CDK4/6 inhibitors for the\n  treatment of HR-positive, HER2-negative locally advanced or metastatic breast\n  cancer subject to the criteria recommended by CaTSoP. No priority given. (May\n  2019).</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"" style="""">second-line</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">High priority in patients with hormone-sensitive disease\n  (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium priority for all second-line patients (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr></tbody></table><p><br></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently three CDK4/6 inhibitors marketed internationally (abemaciclib, palbociclib and ribociclib), each with slightly different dosing schedules, inhibiting CDK4/6 at slightly different concentrations, and each with slightly differing reports of adverse events. However, the Subcommittee considered that currently available evidence indicates there is a class effect from use of these agents in the treatment of HR-positive HER2-negative locally advanced breast cancer. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that three funding applications for two CDK4/6 inhibitor agents (palbociclib and ribociclib) had been previously considered by both PTAC and CaTSoP, however both committees had previously considered the totality of data for the class of agents that was available at the time. </p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following summary of previous consideration and recommendations regarding funding applications for CDK4/6 inhibitors for HR-positive, HER2-negative locally advanced breast cancer:</p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">  </span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""color: white;"">The Subcommittee noted that a fourth application, for ribociclib as a second-line treatment, had been received subsequent to PTAC’s consideration of CDK4/6 inhibitors in May 2019 and that to date no funding application for abemaciclib had been received.</span></p><p>Ribociclib applications</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the primary evidence from ribociclib in the treatment of HR-positive HER2-negative locally advanced breast cancer comes from three studies – MONALEESA 2, MONALEESA 3 and MONALEESA 7.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that MONALEESA‑2 is a phase\xa03 randomized, double-blind, placebo-controlled trial of first-line ribociclib plus letrozole compared with placebo plus letrozole in 668 postmenopausal women with HR-positive, HER2-negative advanced breast cancer (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29718092"" target=""_blank"">Hortobagyi et al. Ann Oncol. 2018;29:1541-7</a>). </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients received ribociclib in 28-day treatment cycles (600\u2009mg/day; 3-weeks-on/1-week-off) until disease progression, unacceptable toxicity, death, or discontinuation for any other reason; and that treatment crossover was not permitted.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The primary end point was locally assessed PFS, per RECIST v1.1 and considered that as compared to centrally assessed endpoints, this could introduce inconsistency to the data. The Subcommittee noted that at a median follow-up of 26.4 months, the median PFS was 25.3 months in the palbociclib arm compared with 16.0 month in the placebo/letrozole arm (HR 0.568; 95% CI 0.457 to 0.704; log-rank P = 9.63 x 10-8). </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the key secondary end point was OS however OS data remained immature, with 50 deaths in the ribociclib arm and 66 in the placebo arm (HR 0.746, 95% CI 0.517 – 1.078).</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the most frequent all-cause grade 3/4 AEs (≥15% in either arm; ribociclib plus letrozole versus placebo plus letrozole) were neutropenia and leukopenia.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that overall, 192 patients (57.5%) in the ribociclib plus letrozole arm had at least one ribociclib/placebo dose reduction versus 26 (7.9%) in the placebo plus letrozole arm; most patients required a single dose reduction [115 (34.4%) versus 20 (6.1%), respectively].</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that quality of life data from MONALEESA-2 indicated that this was not diluted with use of ribociclib over time and the lower pain scores with ribociclib would be clinically meaningful for patients.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that MONALEESA-7 is a phase 3, randomised, double-blind, placebo-controlled trial of ribociclib plus endocrine therapy compared with placebo and endocrine therapy in 672 pre or perimenopausal women with HR-positive, HER2-negative advanced breast cancer who had not previously received a CDK4/6 inhibitor (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29804902"" target=""_blank"">Tripathy et al. Lancet Oncol. 2018;19:904-15</a>). </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that eligibility criteria included locoregionally recurrent or metastatic disease not amenable to curative therapy (eg not candidates for curative surgery or radiotherapy), up to one previous line of chemotherapy for advanced disease, and no previous treatment with a CDK4/6 inhibitor.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that that patients could receive either tamoxifen (36%) or a nonsteroidal aromatase inhibitor (64%) as endocrine therapy all with goserelin. The Subcommittee noted treatment crossover was not permitted and considered this was a similar study design to MONALEESA-2.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the primary endpoint was investigator-assessed progression-free survival and at a median follow-up of 19.2 months, that the median PFS was 23.8 months in the ribociclib arm compared with 13.0 months in the placebo/endocrine therapy arm (HR 0.55; 95% CI 0.44 to 0.69; P&lt;0.0001).</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that median progression-free survival per the central assessment of the independent masked review cohort (n=267) was not reached (95% CI 19·9 months–not reached) among the 133 patients assessed in the ribociclib group and 11·1 months (7·4–16·9) in the 134 patients assessed in the placebo group (HR 0·43, 95% CI 0·29–0·63).</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that overall survival results were not mature at the time of this analysis, with 89 deaths recorded in total at data cut-off (43 [13%] in the ribociclib group and 46 [14%] in the placebo group); and that the study remains masked for further follow-up of overall survival.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that MONALEESA-3 is a phase III, double-blind, placebo-controlled<span style=""color: black;""> trial of </span>ribociclib plus fulvestrant compared with placebo plus fulvestrant in 484 postmenopausal women with HR-positive, HER2-negative advanced (metastatic or locoregionally recurrent disease not amenable to curative treatment) breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29860922"" target=""_blank"">Slamon et al. J Clin Oncol. 2018;36:2465-72</a>). The Subcommittee considered this was a similar trial design to MONALEESA-2 and-7 except for the 2:1 randomisation.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that exclusion criteria included prior treatment with chemotherapy for advanced disease, fulvestrant, or a CDK4/6 inhibitor.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that at a median follow-up of 20.4 months, that the median PFS was 20.5 months in the ribociclib arm compared with 12.8 months in the placebo/fulvestrant arm (HR 0.593; 95% CI 0.480 to 0.732; P&lt;0.001). The Subcommittee noted that the median PFS in patients who were treatment-naïve in this trial was not reached in the ribociclib arm compared with 18.3 months in the placebo/fulvestrant arm.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the OS data were reported as immature by Slamon et al 2018, with a total of 70 deaths (14.5%) were observed in the ribociclib arm versus 50 (20.7%) in the placebo arm.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that Novartis had provided unpublished data from a second OS interim analysis at a median follow-up of 39.4 months, which includes 275 deaths (78% of the total 351 events). The Subcommittee noted that the estimated hazard ratio from this second OS interim analysis was 0.724 (95% CI: 0.568, 0.924; p-value 0.00455). The Subcommittee noted that the p-value threshold to claim significance = 0.01129 and therefore OS was considered to be statistically significant despite median OS having been not reached (NR) in the ribociclib arm and was 40.0 months (95% CI: 37.0, NE) in the placebo arm. The Subcommittee noted that median OS in the treatment-naïve (first-line) subgroup was NR vs 45.1\u2009months (HR, 0.700 [95% CI, 0.479-1.021]) and in the second-line subgroup was 40.2 vs 32.5\u2009months (HR, 0.730 [95% CI, 0.530-1.004]). The Subcommittee noted that this OS data was presented at <a href=""https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Overall-survival-OS-results-of-the-Phase-III-MONALEESA-3-trial-of-postmenopausal-patients-pts-with-hormone-receptor-positive-HR-human-epidermal-growth-factor-2-negative-HER2-advanced-breast-cancer-ABC-treated-with-fulvestrant-FUL-ribocicl"" target=""_blank"">ESMO 2019</a> and that as per protocol, these OS results will be considered final.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that all three MONALEESA studies have shown an OS benefit from use of ribociclib for the treatment of HR-positive HER2-negative advanced breast cancer.</p><p>Advice requested by PTAC </p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that in August 2019 PTAC had recognised that there were some differences in the records of PTAC and CaTSoP’s consideration of the funding applications for these agents (likely based on the different but complementary expertise, experience, and perspectives each committee brought to its consideration under the Factors for Consideration). The Subcommittee noted that PTAC considered it would be useful that CaTSoP clarify its advice about CDK4/6 inhibitors so that PTAC could further consider its priorities and recommendations for this class of agents.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that in particular PTAC asked if CaTSoP could provide a more detailed evidence review and discussion about:</p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>Why the health need of a second-line population was rated higher than the first-line setting, but that the recorded recommendation was that funding of CDK4/6 inhibitors as a class was a lower priority for use in second-line than in first-line. </p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>More details about CaTSoP’s interpretation of the evidence for differences in outcomes such as for overall survival (OS), progression-free survival (PFS), and quality of life in both first- or second-line settings for late breast cancers. </p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>More details about CaTSoP’s assessment the OS benefit, its magnitude, and precision, for the different treatment settings, and the evidence used for this advice.</p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>in the context of CDK4/6 inhibitors, advice on: the strength and quality of available evidence for the use of surrogate outcomes specifically for locally advanced or metastatic breast cancers, particularly those that are HR-positive and/or HER2-negative, and thus the applicability of such outcomes data in this setting.</p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that previously treated (second-line) patients were considered to have a higher health need than those in the first-line population as they would be more symptomatic and have likely to exhaust their endocrine options more quickly. However, the Subcommittee considered that in April 2019 the relative funding priority for all second-line patients was considered to be slightly lower than that in the first-line setting due to the quality of evidence and likely higher absolute level of benefit in terms of PFS and OS in a first-line setting. Although, members noted that this does not include those second-line patients with hormone sensitive disease where the data in this subgroup is considered to be stronger than in a general second-line population.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the updated survival data for ribociclib from MONALEESA-3 and MONALEESA-7 reinforced the signal of a class effect from use of CDK4/6 inhibitors in the treatment of HR-positive HER2-negative advanced breast cancer. </p><p><span style=""color: black;"">1.29.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that benefit from use of CDK4/6 inhibitor has been demonstrated across both first and second-line populations. The Subcommittee considered that the differences in trial results is likely to have been driven by heterogeneity of the trial populations, such as the number of patients with endocrine-sensitive disease or ESR-1 mutation rates, although this was based on expert opinion and not supported by any current data.</p><p><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that a benefit from CDK4/6 inhibitors is reported in both first-line post-menopausal patients and first-line pre-menopausal patients treated with ovarian suppression with the strength of evidence best for those who receive aromatase inhibitor and goserelin. The Subcommittee considered that patients with hormone-sensitive disease appear to get the most benefit from use of a CDK4/6 inhibitor in a second-line setting; and that the durability of response for the overall second-line population is likely to be slightly shorter than when used in a first-line HR-positive HER2-negative advanced breast cancer population.</p><p><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that of the various trials for use of the three CDK4/6 inhibitor agents with currently published evidence, the ribociclib trials were of highest quality due to their clinical trial design, which meant that OS could be demonstrated, whereas the survival data from the palbociclib and abemaciclib trials were compromised by the crossover design.</p><p><span style=""color: black;"">1.32.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that there is good quality evidence that CDK4/6 inhibitors provide a PFS of around 10 to 12 months and around a 30% improvement in OS (in a disease setting where it is difficult to demonstrate OS gain) both of which were clinically meaningful for patients with HR-positive HER2-negative advanced breast cancer. </p><p><span style=""color: black;"">1.33.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that while improving OS is considered the most important therapeutic goal in advanced breast cancer, it has been difficult to demonstrate an OS advantage in clinical trials in advanced breast cancer populations and particularly in a first-line setting. The Subcommittee considered this is both because powering studies to show OS requires very large patient numbers and also because heterogeneous populations with long post progression survival, crossover and heterogeneous post study therapy as well as the evolving treatment standards for these patients all impact on study outcomes.</p><p><span style=""color: black;"">1.34.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that it had considered some of the issues and challenges related to clinical trial design, surrogate outcomes and critical appraisal at its meeting in <a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">July 2019</a>. </p><p><span style=""color: black;"">1.35.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that in advanced breast cancer there is evidence to support the use of surrogate measure, such as PFS, for OS including a number of systematic reviews across a variety of advanced breast cancer patient populations. </p><p><span style=""color: black;"">1.36.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee acknowledged that the quality of these reviews was variable (the number of trials included in these reviews and the number of patients in the trials included differed, some reviews use all lines of therapy whereas some restrict to first or second line) almost all of these reviews addressed the issue of PFS as a surrogate measure for OS in metastatic disease.</p><p><span style=""color: black;"">1.37.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that some reviews did not show any correlation between PFS and OS while other showed a modest correlation (square correlation statistic ranged from 0.1-0.57), however considered that the more tightly the population was defined the better the correlation became for example HR-positive, HER2-negative disease in premenopausal women.</p><p><span style=""color: black;"">1.38.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee also noted a<span style=""color: black;""> study of mBC patients and oncology care providers (</span>nurses<span style=""color: black;""> and oncologists) in the US aimed at evaluating by the value of OS, PFS, and other treatment attributes in treatment decision by surveys designed to assess preferences for OS/PFS and stable disease and the timing thereof, preferences for level of evidence and toxicity rates as well as willingness to pay for specific treatment attributes (</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589981/"" target=""_blank"">MacEwan et al MDM Policy Pract. 2019; 4: 2381468319855386</a><span style=""color: black;"">).</span></p><p>General comments</p><p><span style=""color: black;"">1.39.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that on 1 September 2019, PHARMAC issued a <a href=""https://www.pharmac.govt.nz/news/rfp-2019-09-01-cdk4-cdk6/"" target=""_blank"">Request for Proposals</a> for the supply of a CDK4/CDK6 inhibitor for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer; and that this process was seeking commercial bids from the suppliers of these medicines for use as both first and second-line treatment for patients who meet the Special Authority criteria detailed in the RFP document (as recommended by CaTSoP in April 2019). The Subcommittee considered it would be a preferred outcome for both first and second-line populations to be funded as a result of this competitive process.</p><table class=""ql-table-blob"" border=""1"" style=""width: 441.4pt; margin-left: 28.1pt;"" width=""589""><tbody><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">\xa0</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">\xa0</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p align=""center"" class=""MsoBodyText"" style=""text-align: center;""><b>CaTSoP</b></p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p align=""center"" class=""MsoBodyText"" style=""text-align: center;""><b>PTAC</b></p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""5"" rowspan=""1"" valign=""top"" width=""589"" style=""width: 441.4pt;"">\n  <p class=""MsoBodyText"">Chemical</p>\n  </td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">Palbociclib</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium (September 2018)</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Low (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">second-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Medium (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">Ribociclib</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by CaTSoP</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Low (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">second-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by CaTSoP.</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by PTAC.</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""5"" rowspan=""1"" valign=""top"" width=""589"" style=""width: 441.4pt;"">\n  <p class=""MsoBodyText"">Class </p>\n  </td></tr><tr><td colspan=""1"" rowspan=""3"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">CDK4/6 inhibitors</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">High priority (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""3"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Class effect associated with CDK4/6 inhibitors for the\n  treatment of HR-positive, HER2-negative locally advanced or metastatic breast\n  cancer subject to the criteria recommended by CaTSoP. No priority given. (May\n  2019).</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"" style="""">second-line</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">High priority in patients with hormone-sensitive disease\n  (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium priority for all second-line patients (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr></tbody></table><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered applications from Novartis New Zealand Limited for the use of ribociclib (Kisqali):</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>in combination with fulvestrant for the second-line treatment of HR-positive, HER2-negative locally advanced breast cancer who have failed previous endocrine therapy.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered applications from Novartis New Zealand Limited for the use of ribociclib (Kisqali):</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>in combination with fulvestrant for the second-line treatment of HR-positive, HER2-negative locally advanced breast cancer who have failed previous endocrine therapy.</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In regards to item 9, CDK4/6 inhibitors for the treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, the Committee noted that in paragraph 12.43 these agents were described as providing ‘around a 30% improvement in OS’, but felt more detail would have been useful for PTAC to be able to advise PHARMAC staff about the implications of the magnitude of a survival advantage for decision-making purposes. </p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that as written the record with the general statement of a 30% improvement could have been better put in relation to baseline risks, absolute treatment effects such as quantiles of survival, and in relation to uncertainty, such as provided by point estimates and confidence intervals. The Committee noted the corresponding reporting of PFS for the same study in that same paragraph of the record reported an absolute not relative treatment effect (of around 10 or 12 months), and this would have been more useful with further clarification.</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that a senior statistician had recently been appointed to CaTSoP; and considered this provided valuable opportunities to discuss and review the most accurate, valid and consistent ways to represent trial results presented in the subcommittee records.</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the overall survival data from MONALESSA-7 did not appear to be referenced in the October 2019 record and so it was unclear whether CaTSoP had reviewed this.</p><p>1.1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that paragraph 9.33 of the October record should have stated that ‘all three MONALEESA studies have shown improved PFS and two an OS benefit’.</p><p>1.1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the economic modelling undertaken by PHARMAC for the benefit of CDK4/6 inhibitors for HR-positive HER2-negative locally advanced or metastatic breast cancer used the Kaplan-Meier survival curves in published evidence at source; and considered this to be a sufficiently robust process.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In regards to item 9, CDK4/6 inhibitors for the treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, the Committee noted that in paragraph 12.43 these agents were described as providing ‘around a 30% improvement in OS’, but felt more detail would have been useful for PTAC to be able to advise PHARMAC staff about the implications of the magnitude of a survival advantage for decision-making purposes. </p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that as written the record with the general statement of a 30% improvement could have been better put in relation to baseline risks, absolute treatment effects such as quantiles of survival, and in relation to uncertainty, such as provided by point estimates and confidence intervals. The Committee noted the corresponding reporting of PFS for the same study in that same paragraph of the record reported an absolute not relative treatment effect (of around 10 or 12 months), and this would have been more useful with further clarification.</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that a senior statistician had recently been appointed to CaTSoP; and considered this provided valuable opportunities to discuss and review the most accurate, valid and consistent ways to represent trial results presented in the subcommittee records.</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the overall survival data from MONALESSA-7 did not appear to be referenced in the October 2019 record and so it was unclear whether CaTSoP had reviewed this.</p><p>1.1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that paragraph 9.33 of the October record should have stated that ‘all three MONALEESA studies have shown improved PFS and two an OS benefit’.</p><p>1.1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the economic modelling undertaken by PHARMAC for the benefit of CDK4/6 inhibitors for HR-positive HER2-negative locally advanced or metastatic breast cancer used the Kaplan-Meier survival curves in published evidence at source; and considered this to be a sufficiently robust process.</p>', 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mV2AQ'}, 'Id': 'a0POZ000005f4mV2AQ', 'Event_Date__c': '2019-10-18', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Oct 2019', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that ribociclib in combination with fulvestrant for the second-line treatment of HR-positive, HER2-negative locally advanced breast cancer who have failed previous endocrine therapy be funded with high priority subject to the same Special Authority criteria as previously recommended for palbociclib in this setting.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the different priority assigned to ribociclib and palbociclib was primarily due to differences in the quality of data currently available for these agents.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that based on currently available data there was a class effect from CDK4/6 inhibitors in the treatment of HR-positive HER2-negative locally advanced breast cancer and <b>recommended</b> funding for patients to receive one line of treatment with a CDK4/6 inhibitor in either a first or second-line setting with high priority.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reiterated its previous recommendation that the following Special Authority criteria be applied to funding of CDK4/6 inhibitors (note combined first-line and second-line criteria are shown below):</p><p><span style=""font-size: 9pt;"">Special Authority for Subsidy – Retail Pharmacy</span></p><p><span style=""font-size: 9pt;"">Initial application -</span><b style=""font-size: 9pt;""> </b><span style=""font-size: 9pt;"">only from a medical oncologist or </span><span style=""font-size: 10pt;"">any other </span><span style=""font-size: 9pt;"">medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has unresectable locally advanced or metastatic breast cancer; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming disease is hormone-receptor positive and HER2-negative; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance score of 0-2; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has relapsed or progressed during prior endocrine therapy; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior systemic treatment for metastatic disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[CDK4/6 inhibitor] must be used in combination with an endocrine partner.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Renewal application - only from a medical oncologist or </span><span style=""font-size: 10pt;"">any other </span><span style=""font-size: 9pt;"">medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[CDK4/6 inhibitor] must be used in combination with an endocrine partner; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of progressive disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate and the patient is benefitting from treatment.</span></p><p><br></p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered applications from Novartis New Zealand Limited for the use of ribociclib (Kisqali):</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>in combination with fulvestrant for the second-line treatment of HR-positive, HER2-negative locally advanced breast cancer who have failed previous endocrine therapy.</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently three CDK4/6 inhibitors marketed internationally (abemaciclib, palbociclib and ribociclib), each with slightly different dosing schedules, inhibiting CDK4/6 at slightly different concentrations, and each with slightly differing reports of adverse events. However, the Subcommittee considered that currently available evidence indicates there is a class effect from use of these agents in the treatment of HR-positive HER2-negative locally advanced breast cancer. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that three funding applications for two CDK4/6 inhibitor agents (palbociclib and ribociclib) had been previously considered by both PTAC and CaTSoP, however both committees had previously considered the totality of data for the class of agents that was available at the time. </p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following summary of previous consideration and recommendations regarding funding applications for CDK4/6 inhibitors for HR-positive, HER2-negative locally advanced breast cancer:</p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">  </span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""color: white;"">The Subcommittee noted that a fourth application, for ribociclib as a second-line treatment, had been received subsequent to PTAC’s consideration of CDK4/6 inhibitors in May 2019 and that to date no funding application for abemaciclib had been received.</span></p><p>Ribociclib applications</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the primary evidence from ribociclib in the treatment of HR-positive HER2-negative locally advanced breast cancer comes from three studies – MONALEESA 2, MONALEESA 3 and MONALEESA 7.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that MONALEESA‑2 is a phase\xa03 randomized, double-blind, placebo-controlled trial of first-line ribociclib plus letrozole compared with placebo plus letrozole in 668 postmenopausal women with HR-positive, HER2-negative advanced breast cancer (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29718092"" target=""_blank"">Hortobagyi et al. Ann Oncol. 2018;29:1541-7</a>). </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients received ribociclib in 28-day treatment cycles (600\u2009mg/day; 3-weeks-on/1-week-off) until disease progression, unacceptable toxicity, death, or discontinuation for any other reason; and that treatment crossover was not permitted.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The primary end point was locally assessed PFS, per RECIST v1.1 and considered that as compared to centrally assessed endpoints, this could introduce inconsistency to the data. The Subcommittee noted that at a median follow-up of 26.4 months, the median PFS was 25.3 months in the palbociclib arm compared with 16.0 month in the placebo/letrozole arm (HR 0.568; 95% CI 0.457 to 0.704; log-rank P = 9.63 x 10-8). </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the key secondary end point was OS however OS data remained immature, with 50 deaths in the ribociclib arm and 66 in the placebo arm (HR 0.746, 95% CI 0.517 – 1.078).</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the most frequent all-cause grade 3/4 AEs (≥15% in either arm; ribociclib plus letrozole versus placebo plus letrozole) were neutropenia and leukopenia.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that overall, 192 patients (57.5%) in the ribociclib plus letrozole arm had at least one ribociclib/placebo dose reduction versus 26 (7.9%) in the placebo plus letrozole arm; most patients required a single dose reduction [115 (34.4%) versus 20 (6.1%), respectively].</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that quality of life data from MONALEESA-2 indicated that this was not diluted with use of ribociclib over time and the lower pain scores with ribociclib would be clinically meaningful for patients.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that MONALEESA-7 is a phase 3, randomised, double-blind, placebo-controlled trial of ribociclib plus endocrine therapy compared with placebo and endocrine therapy in 672 pre or perimenopausal women with HR-positive, HER2-negative advanced breast cancer who had not previously received a CDK4/6 inhibitor (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29804902"" target=""_blank"">Tripathy et al. Lancet Oncol. 2018;19:904-15</a>). </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that eligibility criteria included locoregionally recurrent or metastatic disease not amenable to curative therapy (eg not candidates for curative surgery or radiotherapy), up to one previous line of chemotherapy for advanced disease, and no previous treatment with a CDK4/6 inhibitor.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that that patients could receive either tamoxifen (36%) or a nonsteroidal aromatase inhibitor (64%) as endocrine therapy all with goserelin. The Subcommittee noted treatment crossover was not permitted and considered this was a similar study design to MONALEESA-2.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the primary endpoint was investigator-assessed progression-free survival and at a median follow-up of 19.2 months, that the median PFS was 23.8 months in the ribociclib arm compared with 13.0 months in the placebo/endocrine therapy arm (HR 0.55; 95% CI 0.44 to 0.69; P&lt;0.0001).</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that median progression-free survival per the central assessment of the independent masked review cohort (n=267) was not reached (95% CI 19·9 months–not reached) among the 133 patients assessed in the ribociclib group and 11·1 months (7·4–16·9) in the 134 patients assessed in the placebo group (HR 0·43, 95% CI 0·29–0·63).</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that overall survival results were not mature at the time of this analysis, with 89 deaths recorded in total at data cut-off (43 [13%] in the ribociclib group and 46 [14%] in the placebo group); and that the study remains masked for further follow-up of overall survival.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that MONALEESA-3 is a phase III, double-blind, placebo-controlled<span style=""color: black;""> trial of </span>ribociclib plus fulvestrant compared with placebo plus fulvestrant in 484 postmenopausal women with HR-positive, HER2-negative advanced (metastatic or locoregionally recurrent disease not amenable to curative treatment) breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29860922"" target=""_blank"">Slamon et al. J Clin Oncol. 2018;36:2465-72</a>). The Subcommittee considered this was a similar trial design to MONALEESA-2 and-7 except for the 2:1 randomisation.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that exclusion criteria included prior treatment with chemotherapy for advanced disease, fulvestrant, or a CDK4/6 inhibitor.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that at a median follow-up of 20.4 months, that the median PFS was 20.5 months in the ribociclib arm compared with 12.8 months in the placebo/fulvestrant arm (HR 0.593; 95% CI 0.480 to 0.732; P&lt;0.001). The Subcommittee noted that the median PFS in patients who were treatment-naïve in this trial was not reached in the ribociclib arm compared with 18.3 months in the placebo/fulvestrant arm.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the OS data were reported as immature by Slamon et al 2018, with a total of 70 deaths (14.5%) were observed in the ribociclib arm versus 50 (20.7%) in the placebo arm.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that Novartis had provided unpublished data from a second OS interim analysis at a median follow-up of 39.4 months, which includes 275 deaths (78% of the total 351 events). The Subcommittee noted that the estimated hazard ratio from this second OS interim analysis was 0.724 (95% CI: 0.568, 0.924; p-value 0.00455). The Subcommittee noted that the p-value threshold to claim significance = 0.01129 and therefore OS was considered to be statistically significant despite median OS having been not reached (NR) in the ribociclib arm and was 40.0 months (95% CI: 37.0, NE) in the placebo arm. The Subcommittee noted that median OS in the treatment-naïve (first-line) subgroup was NR vs 45.1\u2009months (HR, 0.700 [95% CI, 0.479-1.021]) and in the second-line subgroup was 40.2 vs 32.5\u2009months (HR, 0.730 [95% CI, 0.530-1.004]). The Subcommittee noted that this OS data was presented at <a href=""https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Overall-survival-OS-results-of-the-Phase-III-MONALEESA-3-trial-of-postmenopausal-patients-pts-with-hormone-receptor-positive-HR-human-epidermal-growth-factor-2-negative-HER2-advanced-breast-cancer-ABC-treated-with-fulvestrant-FUL-ribocicl"" target=""_blank"">ESMO 2019</a> and that as per protocol, these OS results will be considered final.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that all three MONALEESA studies have shown an OS benefit from use of ribociclib for the treatment of HR-positive HER2-negative advanced breast cancer.</p><p>Advice requested by PTAC </p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that in August 2019 PTAC had recognised that there were some differences in the records of PTAC and CaTSoP’s consideration of the funding applications for these agents (likely based on the different but complementary expertise, experience, and perspectives each committee brought to its consideration under the Factors for Consideration). The Subcommittee noted that PTAC considered it would be useful that CaTSoP clarify its advice about CDK4/6 inhibitors so that PTAC could further consider its priorities and recommendations for this class of agents.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that in particular PTAC asked if CaTSoP could provide a more detailed evidence review and discussion about:</p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>Why the health need of a second-line population was rated higher than the first-line setting, but that the recorded recommendation was that funding of CDK4/6 inhibitors as a class was a lower priority for use in second-line than in first-line. </p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>More details about CaTSoP’s interpretation of the evidence for differences in outcomes such as for overall survival (OS), progression-free survival (PFS), and quality of life in both first- or second-line settings for late breast cancers. </p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>More details about CaTSoP’s assessment the OS benefit, its magnitude, and precision, for the different treatment settings, and the evidence used for this advice.</p><p><span style="""">o</span><span style=""font-size: 7pt;"">\xa0\xa0</span>in the context of CDK4/6 inhibitors, advice on: the strength and quality of available evidence for the use of surrogate outcomes specifically for locally advanced or metastatic breast cancers, particularly those that are HR-positive and/or HER2-negative, and thus the applicability of such outcomes data in this setting.</p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that previously treated (second-line) patients were considered to have a higher health need than those in the first-line population as they would be more symptomatic and have likely to exhaust their endocrine options more quickly. However, the Subcommittee considered that in April 2019 the relative funding priority for all second-line patients was considered to be slightly lower than that in the first-line setting due to the quality of evidence and likely higher absolute level of benefit in terms of PFS and OS in a first-line setting. Although, members noted that this does not include those second-line patients with hormone sensitive disease where the data in this subgroup is considered to be stronger than in a general second-line population.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the updated survival data for ribociclib from MONALEESA-3 and MONALEESA-7 reinforced the signal of a class effect from use of CDK4/6 inhibitors in the treatment of HR-positive HER2-negative advanced breast cancer. </p><p><span style=""color: black;"">1.29.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that benefit from use of CDK4/6 inhibitor has been demonstrated across both first and second-line populations. The Subcommittee considered that the differences in trial results is likely to have been driven by heterogeneity of the trial populations, such as the number of patients with endocrine-sensitive disease or ESR-1 mutation rates, although this was based on expert opinion and not supported by any current data.</p><p><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that a benefit from CDK4/6 inhibitors is reported in both first-line post-menopausal patients and first-line pre-menopausal patients treated with ovarian suppression with the strength of evidence best for those who receive aromatase inhibitor and goserelin. The Subcommittee considered that patients with hormone-sensitive disease appear to get the most benefit from use of a CDK4/6 inhibitor in a second-line setting; and that the durability of response for the overall second-line population is likely to be slightly shorter than when used in a first-line HR-positive HER2-negative advanced breast cancer population.</p><p><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that of the various trials for use of the three CDK4/6 inhibitor agents with currently published evidence, the ribociclib trials were of highest quality due to their clinical trial design, which meant that OS could be demonstrated, whereas the survival data from the palbociclib and abemaciclib trials were compromised by the crossover design.</p><p><span style=""color: black;"">1.32.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that there is good quality evidence that CDK4/6 inhibitors provide a PFS of around 10 to 12 months and around a 30% improvement in OS (in a disease setting where it is difficult to demonstrate OS gain) both of which were clinically meaningful for patients with HR-positive HER2-negative advanced breast cancer. </p><p><span style=""color: black;"">1.33.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that while improving OS is considered the most important therapeutic goal in advanced breast cancer, it has been difficult to demonstrate an OS advantage in clinical trials in advanced breast cancer populations and particularly in a first-line setting. The Subcommittee considered this is both because powering studies to show OS requires very large patient numbers and also because heterogeneous populations with long post progression survival, crossover and heterogeneous post study therapy as well as the evolving treatment standards for these patients all impact on study outcomes.</p><p><span style=""color: black;"">1.34.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that it had considered some of the issues and challenges related to clinical trial design, surrogate outcomes and critical appraisal at its meeting in <a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">July 2019</a>. </p><p><span style=""color: black;"">1.35.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that in advanced breast cancer there is evidence to support the use of surrogate measure, such as PFS, for OS including a number of systematic reviews across a variety of advanced breast cancer patient populations. </p><p><span style=""color: black;"">1.36.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee acknowledged that the quality of these reviews was variable (the number of trials included in these reviews and the number of patients in the trials included differed, some reviews use all lines of therapy whereas some restrict to first or second line) almost all of these reviews addressed the issue of PFS as a surrogate measure for OS in metastatic disease.</p><p><span style=""color: black;"">1.37.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that some reviews did not show any correlation between PFS and OS while other showed a modest correlation (square correlation statistic ranged from 0.1-0.57), however considered that the more tightly the population was defined the better the correlation became for example HR-positive, HER2-negative disease in premenopausal women.</p><p><span style=""color: black;"">1.38.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee also noted a<span style=""color: black;""> study of mBC patients and oncology care providers (</span>nurses<span style=""color: black;""> and oncologists) in the US aimed at evaluating by the value of OS, PFS, and other treatment attributes in treatment decision by surveys designed to assess preferences for OS/PFS and stable disease and the timing thereof, preferences for level of evidence and toxicity rates as well as willingness to pay for specific treatment attributes (</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589981/"" target=""_blank"">MacEwan et al MDM Policy Pract. 2019; 4: 2381468319855386</a><span style=""color: black;"">).</span></p><p>General comments</p><p><span style=""color: black;"">1.39.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that on 1 September 2019, PHARMAC issued a <a href=""https://www.pharmac.govt.nz/news/rfp-2019-09-01-cdk4-cdk6/"" target=""_blank"">Request for Proposals</a> for the supply of a CDK4/CDK6 inhibitor for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer; and that this process was seeking commercial bids from the suppliers of these medicines for use as both first and second-line treatment for patients who meet the Special Authority criteria detailed in the RFP document (as recommended by CaTSoP in April 2019). The Subcommittee considered it would be a preferred outcome for both first and second-line populations to be funded as a result of this competitive process.</p><table class=""ql-table-blob"" border=""1"" style=""width: 441.4pt; margin-left: 28.1pt;"" width=""589""><tbody><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">\xa0</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">\xa0</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p align=""center"" class=""MsoBodyText"" style=""text-align: center;""><b>CaTSoP</b></p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p align=""center"" class=""MsoBodyText"" style=""text-align: center;""><b>PTAC</b></p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""5"" rowspan=""1"" valign=""top"" width=""589"" style=""width: 441.4pt;"">\n  <p class=""MsoBodyText"">Chemical</p>\n  </td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">Palbociclib</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium (September 2018)</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Low (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">second-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Medium (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">Ribociclib</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by CaTSoP</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Low (May 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">second-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by CaTSoP.</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Application not previously considered by PTAC.</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""5"" rowspan=""1"" valign=""top"" width=""589"" style=""width: 441.4pt;"">\n  <p class=""MsoBodyText"">Class </p>\n  </td></tr><tr><td colspan=""1"" rowspan=""3"" valign=""top"" width=""94"" style=""width: 70.65pt;"">\n  <p class=""MsoBodyText"">CDK4/6 inhibitors</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"">first-line </p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">High priority (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""3"" valign=""top"" width=""201"" style=""width: 150.7pt;"">\n  <p class=""MsoBodyText"">Class effect associated with CDK4/6 inhibitors for the\n  treatment of HR-positive, HER2-negative locally advanced or metastatic breast\n  cancer subject to the criteria recommended by CaTSoP. No priority given. (May\n  2019).</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""2"" valign=""top"" width=""94"" style=""width: 70.85pt;"">\n  <p class=""MsoBodyText"" style="""">second-line</p>\n  </td><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">High priority in patients with hormone-sensitive disease\n  (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr><tr><td colspan=""1"" rowspan=""1"" valign=""top"" width=""198"" style=""width: 148.85pt;"">\n  <p class=""MsoBodyText"">Medium priority for all second-line patients (April 2019)</p>\n  </td><td colspan=""1"" rowspan=""1"" style="""" width=""0""><p class=""MsoNormal"">\xa0</p></td></tr></tbody></table><p><br></p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In regards to item 9, CDK4/6 inhibitors for the treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, the Committee noted that in paragraph 12.43 these agents were described as providing ‘around a 30% improvement in OS’, but felt more detail would have been useful for PTAC to be able to advise PHARMAC staff about the implications of the magnitude of a survival advantage for decision-making purposes. </p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that as written the record with the general statement of a 30% improvement could have been better put in relation to baseline risks, absolute treatment effects such as quantiles of survival, and in relation to uncertainty, such as provided by point estimates and confidence intervals. The Committee noted the corresponding reporting of PFS for the same study in that same paragraph of the record reported an absolute not relative treatment effect (of around 10 or 12 months), and this would have been more useful with further clarification.</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that a senior statistician had recently been appointed to CaTSoP; and considered this provided valuable opportunities to discuss and review the most accurate, valid and consistent ways to represent trial results presented in the subcommittee records.</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the overall survival data from MONALESSA-7 did not appear to be referenced in the October 2019 record and so it was unclear whether CaTSoP had reviewed this.</p><p>1.1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that paragraph 9.33 of the October record should have stated that ‘all three MONALEESA studies have shown improved PFS and two an OS benefit’.</p><p>1.1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the economic modelling undertaken by PHARMAC for the benefit of CDK4/6 inhibitors for HR-positive HER2-negative locally advanced or metastatic breast cancer used the Kaplan-Meier survival curves in published evidence at source; and considered this to be a sufficiently robust process.</p>', 'Status_History__c': 'a132P000000BUmUQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mX2AQ'}, 'Id': 'a0POZ000005f4mX2AQ', 'Event_Date__c': '2020-02-23', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BUlqQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4ma2AA'}, 'Id': 'a0POZ000005f4ma2AA', 'Event_Date__c': '2023-06-30', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a13OZ000003pSN7YAM'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from  at meeting TBD.', 'fs': 'Clinical advice received from  at meeting TBD.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4me2AA'}, 'Id': 'a0POZ000005f4me2AA', 'Event_Date__c': '2023-11-21', 'Event_Description__c': 'Clinical advice received from  at meeting TBD.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000006DeyqYAC'}, 'change': None}]",Oct 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mY2AQ'}, 'Id': 'a0POZ000005f4mY2AQ', 'Event_Date__c': '2020-05-15', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BlGlQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mb2AA'}, 'Id': 'a0POZ000005f4mb2AA', 'Event_Date__c': '2023-08-21', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2023', 'Status_History__c': 'a13OZ000001YmpeYAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2023', 'fs': 'Oct 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mc2AA'}, 'Id': 'a0POZ000005f4mc2AA', 'Event_Date__c': '2023-10-02', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Oct 2023', 'Status_History__c': 'a13OZ000002RNabYAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2023', 'fs': 'Oct 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4md2AA'}, 'Id': 'a0POZ000005f4md2AA', 'Event_Date__c': '2023-10-02', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Oct 2023', 'Status_History__c': 'a13OZ000002RZLVYA4'}, 'change': None}]",May 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mZ2AQ'}, 'Id': 'a0POZ000005f4mZ2AQ', 'Event_Date__c': '2020-06-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BtQwQAK'}, 'change': None}]",Jun 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mf2AA'}, 'Id': 'a0POZ000005f4mf2AA', 'Event_Date__c': '2023-12-12', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000006Dk02YAC'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2024', 'fs': 'Jan 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mg2AA'}, 'Id': 'a0POZ000005f4mg2AA', 'Event_Date__c': '2024-01-10', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jan 2024', 'Status_History__c': 'a13OZ000006DkUeYAK'}, 'change': None}]",Jan 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-treatments-for-breast-cancer-and-leukaemia', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-treatments-for-breast-cancer-and-leukaemia', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005f4mh2AA'}, 'Id': 'a0POZ000005f4mh2AA', 'Event_Date__c': '2024-02-26', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-treatments-for-breast-cancer-and-leukaemia', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000007IIYmYAO'}, 'change': None}]",Feb 2024,False,True
